– In the Usa, the Fda has approved for the first time a drug against postpartum depression, the brexanolone
The therapy, explains the press release of the agency, has been shown in clinical tests to be able to decrease the symptoms for at least 30 days.
The medication, explains the press release of the Fda, is administered in hospital by intravenous infusion of the duration of 60 hours, always under the supervision of a doctor for the risk of loss of knowledge. “Postpartum depression is a very serious problem which, in serious cases, put at risk the life – stresses Tiffany Farchione of the Fda. Women can have thoughts autolesionisti or threatening to the child. This approval marks the first time a drug has been specifically approved to treat depression, post-partum, and is an important treatment option”. The medication is under approval by the Ema, reports the manufacturer on its website, the european agency that has granted it the status ‘First’, that should speed up the process.
The first drug approved in the Usa specifically for the postpartum depression represents a turning point for the lives of millions of women around the world affected by the disorder (about a new mother out of nine) that can occur in severe form, putting in danger the life of the woman and child and which now had no treatment solution. It refers to the LOOP Graziano Pinna, neuroscenziato and psychiatrist at the University of Illinois at Chicago, commenting on the ok of the FDA ‘brexanolone’, a slightly modified form of a ‘natural tranquilizer’ produced in the brain called “allopregnanolone”.
The disturbance that stresses Fin, if not treated can last for months and even years, is caused by a rapid decrease, which occurs immediately after delivery, the steroid hormones such as progesterone, but especially of allopregnanolone. “My workshop – as reported by Fin – during years of research in this field has for the first time demonstrated that this molecule, also produced in the brain, plays important physiological roles as a ‘tranquilizer endogenous’, ensuring the proper functioning of brain areas that regulate mood”. The brexanolone ensures the new mother to restore the function, that is to miss the dramatic decrease of the endogenous levels of steroids, continuous Fin.
“The benefits of this treatment – said the expert – are huge, in fact, not only the antidepressant effects occur after a few hours of administration, but are also durable in time, in fact the symptoms did not recur in 94% of patients treated.
This is a big step forward compared to the antidepressant treatments used to date have low effectiveness, they begin to work after weeks, and are associated with relapse.
The brexanolone – concluded-Fin – represents one of the first antidepressant drugs of new generation, fast-acting, with future applications for major depression and probably other mood disorders as the disorder post-traumatic stress disorder”. .